NCT01187628View on ClinicalTrials.gov

Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

PHASE3CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Hyperphosphatemia
Interventions
DRUG

Fosrenol (Lanthanum Carbonate, BAY77-1931)

Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.

Trial Locations (40)

446-8602

Anjo

455-8530

Nagoya

457-8510

Nagoya

460-0001

Nagoya

466-8650

Nagoya

489-8642

Seto

441-8021

Toyohashi

498-8502

Yatomi

296-0041

Kamogawa

292-8535

Kisarazu

810-8563

Fukuoka

814-0180

Fukuoka

802-0001

Kitakyushu

805-0050

Kitakyushu

811-3195

Koga

063-0005

Sapporo

660-0828

Amagasaki

251-8550

Fujisawa

247-8533

Kamakura

231-8682

Yokohama

234-8503

Yokohama

612-8555

Kyoto

874-0011

Beppu

870-0263

Ōita

710-8602

Kurashiki

700-0013

Okayama

530-0012

Osaka

530-8480

Osaka

534-0021

Osaka

558-8558

Osaka

591-8025

Sakai

840-0054

Saga

421-0193

Shizuoka

770-0011

Tokushima

136-0075

Koto

152-8902

Meguro-ku

105-8471

Minato-ku

180-8610

Musashino

141-8625

Shinagawa

641-8510

Wakayama

Sponsors

Lead Sponsor

Bayer

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Bayer

INDUSTRY

NCT01187628 - Long-term Study in Chronic Kidney Disease (Extension From Study 14817) | Biotech Hunter | Biotech Hunter